Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Basil F. El-Rayes"'
Autor:
James A. Knol, Philip A. Philip, Joel K. Greenson, Edgar Ben-Josef, Sameer P. Desai, Emina Huang, Kent A. Griffith, Basil F. El-Rayes, Mark M. Zalupski, Cornelius J. McGinn
Publikováno v:
American Journal of Clinical Oncology. 30:340-345
Objectives: The purpose of this study was to evaluate the safety and efficacy of preoperative capecitabine and radiation therapy (RT) in patients with locally advanced rectal cancer (LARC). Methods: Patients with adenocarcinoma of the rectum stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25010b0432522bf19b86997dd4f2837c
https://doi.org/10.1097/coc.0b013e318033ed63
https://doi.org/10.1097/coc.0b013e318033ed63
Autor:
Basil F. El-Rayes, Patricia LoRusso, Anthony F. Shields, Shirish M. Gadgeel, Philip A. Philip, Stephanie G. Manza
Publikováno v:
Clinical Cancer Research. 12:7059-7062
Purpose: Bryostatin 1 is a macrocyclic lactone with protein kinase C inhibitory activity. Gemcitabine is a nucleotide analogue with a broad spectrum of anticancer activity. Bryostatin 1 enhanced the activity of antitumor agents including gemcitabine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbcaac58de236f703fe74fbbf75fe303
https://doi.org/10.1158/1078-0432.ccr-06-1419
https://doi.org/10.1158/1078-0432.ccr-06-1419
Autor:
Patricia LoRusso, Ralph E. Parchment, Shirish M. Gadgeel, Basil F. El-Rayes, Philip A. Philip
Publikováno v:
Investigational New Drugs. 24:305-310
Background. Flavopiridol is a cyclin dependent kinase inhibitor. Preclinical models suggest a sequence dependent synergy between flavopiridol and taxanes. The primary objective of this study was to determine the maximum tolerated dose (MTD) of flavop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df15c1ebb00f99c1da18248e2159221f
https://doi.org/10.1007/s10637-005-4343-5
https://doi.org/10.1007/s10637-005-4343-5
Publikováno v:
Molecular Cancer Therapeutics. 4:1943-1951
The aims of this study were to determine the effects of (a) combining the epidermal growth factor receptor (EGFR) blocker (erlotinib) and the cyclooxygenase-2 inhibitor (celecoxib) on cell growth and apoptosis in human pancreatic cancer cell lines, (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89731d96a99775bbeb10925135423bfc
https://doi.org/10.1158/1535-7163.mct-05-0065
https://doi.org/10.1158/1535-7163.mct-05-0065
Autor:
Raghu Venkatramanamoorthy, Mark M. Zalupski, Lance K. Heilbrun, Philip A. Philip, Volkan Adsay, Anthony F. Shields, Basil F. El-Rayes, Ulka N. Vaishampayan, Ann Marie Ferris
Publikováno v:
Investigational New Drugs. 23:583-590
Summary Background .P ancreatic cancer is amongst the most chemoresistant malignancies. Expression of the cyclooxygenase-2 (COX-2) enzyme plays a major role in tumor progression and resistance to therapy. A Phase II study was undertaken to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a09b5c0f1044b6ba347427db56fe121e
https://doi.org/10.1007/s10637-005-1028-z
https://doi.org/10.1007/s10637-005-1028-z
Publikováno v:
Breast Cancer Research and Treatment. 90:25-31
Purpose. Flavopiridol is a novel cyclin dependent kinase (cdk) inhibitor currently in Phase I and II clinical trials. We investigated the interaction between flavopiridol and gemcitabine in two human breast cancer cell lines. Experimental design. MCF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa07db0871c5a63d12a08a52dcc8be01
https://doi.org/10.1007/s10549-004-2179-x
https://doi.org/10.1007/s10549-004-2179-x
Publikováno v:
Molecular Cancer Therapeutics. 3:1421-1426
Cyclooxygenase-2 (COX-2) is involved in inhibition of apoptosis, potentiation of cell growth, and angiogenesis and as such is a target for drug development. The COX-2 enzyme is frequently overexpressed in pancreatic cancer. The aim of this study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b60eb1dcbd6a5a37d61abdf13ddb77af
https://doi.org/10.1158/1535-7163.1421.3.11
https://doi.org/10.1158/1535-7163.1421.3.11
Autor:
Omar Kucuk, Basil F. El-Rayes, Philip A. Philip, Lance K. Heilbrun, Fazlul H. Sarkar, John F. Ensley, Shadan Ali
Publikováno v:
Clinical Cancer Research. 10:4412-4416
Purpose: The cytochrome P-450 (CYP) and glutathione S-transferase (GST) enzyme systems modulate the carcinogenic effects of tobacco. Therefore, the expression of these enzymes may be in part responsible for the observed interindividual and inter-raci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7144636a976303f76b715c050c232a4
https://doi.org/10.1158/1078-0432.ccr-04-0145
https://doi.org/10.1158/1078-0432.ccr-04-0145
Autor:
Mark M. Zalupski, Ann Marie Ferris, Vikash Jain, Philip A. Philip, Anthony F. Shields, D. Terry, Lance K. Heilbrun, Basil F. El-Rayes
Publikováno v:
Annals of Oncology. 15:960-965
Background This study was conducted to evaluate the efficacy and toxicity of combination carboplatin and paclitaxel in patients with esophageal cancer. Materials and methods Thirty-five patients were enrolled. Patients were treated with paclitaxel 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a729d03c78a208042086fe2ad0d65e43
https://doi.org/10.1093/annonc/mdh230
https://doi.org/10.1093/annonc/mdh230
Autor:
Vainutis K. Vaitkevicius, Philip A. Philip, Jay Burmeister, Basil F. El-Rayes, P McDermott, Anthony F. Shields, Ulka N. Vaishampayan, Todd Bossenberger, Edgar Ben-Josef
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 59:454-459
Purpose Local failure continues to be a major problem in the management of pancreatic cancer. Delivery of adequate radiation doses to the pancreas is limited by radiation-sensitive normal structures in the upper abdomen. To overcome some of these res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a4b189ca61a544407653f600f314d59
https://doi.org/10.1016/j.ijrobp.2003.11.019
https://doi.org/10.1016/j.ijrobp.2003.11.019